|
GSK sees positive results on asthma, COPD drug expected to succeed Advair
MedCity News The results boost the compound's prospects as a successor to GSK's blockbuster asthma and COPD drug Advair, whose patents have expired. London-based GSK, which maintains its US headquarters in Research Triangle Park, North Carolina, and drug partner … GSK gets good news on asthma drug Glaxo Drug Gets Positive Trial Results Theravance, Glaxo Lung Drug Passes Two Pivotal Trials; Two More to Go |
View full post on asthma – Google News